Today, the value of this approach is widely recognised even by most pharmaceutical companies, a number of which – including Sanofi, Roche and Genentech, Bayer, and Merck KgaA – have partnered with ...

Is Recursion Pharma a buy because of Nvidia’s endorsement? Indeed, Nvidia’s bet on Recursion is notable, but despite the stake and collaboration, the name isn’t without its fair share of risks.

Recursion Pharmaceuticals (RXRX 0.02%), a biotech company focused on artificial intelligence (AI), went public in April 2021. This was before ChatGPT, before AI became the hottest ...

Self-Referential Large Models: Recursive Self-Enhancement in Code Generation ...

Milestone Payment Triggered by Initiation of Additional Preclinical Studies for REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia –– Extends Cash Runway through 2027 –NEW ...

Rallybio (RLYB) announced that it received an equity milestone payment of $12.5M from Recursion Pharmaceuticals (RXRX). The milestone payment was ...

The most profound failures in history are not those that bet big and lost, but those that failed to bet at all. Incremental advances will never cure Alzheimer’s disease or reverse climate change. To ...

According to data compiled by S&P Global Market Intelligence, Recursion Pharmaceuticals (RXRX -3.49%) stock was shedding more than 17% of its value week-to-date as of Thursday night.

Few movie moments match the spinning top in Inception, which left audiences questioning reality. Christopher Nolan’s 2010 ...

New research explores how prolonged AI interactions can, at least for some users, start to blur the lines between reality and fantasy. Simple interventions could prevent tragic outcomes.